Ladenburg Thalmann Downgrades XOMA, Ltd. (XOMA) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Jefferies Downgrades XOMA, Ltd. (XOMA) to Hold
July 23, 2015 7:23 AM EDTJefferies downgraded XOMA, Ltd. (NASDAQ: XOMA) from Buy to Hold with a price target of $1.00 (from $7.00).
Analyst Biren Amin commented, "XOMA announced that gevokizumab missed on the primary endpoint on time to first exacerbation in EYEGUARD-B for Behcets uveitis as a result of... More
RBC Capital Downgrades XOMA, Ltd. (XOMA) to Sector Perform
July 22, 2015 1:38 PM EDTRBC Capital downgraded XOMA, Ltd. (NASDAQ: XOMA) from Outperform to Sector Perform with a price target of $2.00 (from $8.00).
Analyst Adnan Butt said, "Phase III Behcets study was higher risk but going forward is likely to create uncertainty around Phase III... More
Cowen Downgrades XOMA, Ltd. (XOMA) to Market Perform
July 22, 2015 12:57 PM EDTCowen downgraded XOMA, Ltd. (NASDAQ: XOMA) from Outperform to Market Perform after the company announced that gevo's EYEGUARD-B trial in Behçets uveitis did not meet its primary endpoint. The firm said the gevo's viability is now in question.
Analsyt Phil Nadeau... More
It's NOT 'Game Over' for XOMA (XOMA), Wedbush Says; PT to $13
July 22, 2015 12:55 PM EDTWedbush analyst Liana Moussatos cut here price target on XOMA, Ltd. (NASDAQ: XOMA) to $13.00 (from $17.00) after Gevokizumab failed to meet the primary endpoint in its Phase 3 EYEGUARDB trial in patients with Behçets disease uveitis (BDU). However, the firm maintained its Outperform rating saying it is... More
Piper Jaffray Downgrades XOMA, Ltd. (XOMA) to Neutral
July 22, 2015 11:11 AM EDTPiper Jaffray downgraded XOMA, Ltd. (NASDAQ: XOMA) from Overweight to Neutral.
For an analyst ratings summary and ratings history on XOMA, Ltd. click here. For more ratings news on XOMA, Ltd. click here.
Shares of XOMA, Ltd. closed at $4.40 yesterday.
... MoreXOMA (XOMA) Slammed 70% as Trading Resumes
July 22, 2015 8:33 AM EDTXOMA (NASDAQ: XOMA) has resumed trading and is down 67% after announcing the Phase 3 EYEGUARD-B study of gevokizumab in patients with Bechet's disease uveitis, run by its partner Servier, did not meet the primary endpoint of time to first acute ocular exacerbation.
... MoreXOMA (XOMA) to Resume Trading at 8:30 AM
July 22, 2015 8:03 AM EDTXOMA (NASDAQ: XOMA) to Resume Trading at 8:30 AM
... MoreXOMA (XOMA) Announced Phase 3 EYEGUARD-B Missed Primary Objective
July 22, 2015 8:01 AM EDTXOMA (NASDAQ: XOMA) announced the Phase 3 EYEGUARD-B study of gevokizumab in patients with Behçet's disease uveitis, run by its partner Servier, an independent French pharmaceutical research company driven by the pursuit of innovative drugs, did not meet the primary endpoint of time to first acute ocular exacerbation.
"Although the study did not achieve its main objective, we did see signals of drug activity such as preserved visual acuity, less severe ocular exacerbations... More
XOMA (XOMA) halted with news pending
July 22, 2015 7:57 AM EDTXOMA (NASDAQ: XOMA) halted with news pending.
... More